Antoinette Tan, MD, MHS, discusses the safety profiles of ADCs and ADC selection considerations for breast cancer.
Antoinette Tan, MD, MHS
Advertisement
Antoinette Tan, MD, MHS, is chief of Breast Medical Oncology and co-director of the Phase I Program at Levine Cancer Institute, Carolinas HealthCare System; chief of Medical Oncology at Carolinas Medical Center-Pineville; and a Clinical Professor in the Department of Medicine at the University of North Carolina
Articles by Antoinette Tan, MD, MHS
Antoinette Tan, MD, MHS, discusses the implications of the DESTINY-Breast06 trial of T-DXd vs chemotherapy in HER2-low or -ultralow breast cancer.
Advertisement
Latest Updated Articles
Dr Tan on the Clinical Relevance of T-DXd in HER2-Low/Ultralow Metastatic Breast CancerPublished: July 11th 2025 | Updated:
Dr Tan on the Management of ADC-Related Toxicities in Breast CancerPublished: August 28th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5